Onco Actu du 21 mars 2017

	4.9 Dép., diag. & prono. - Sein
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy [Genomic Health] New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy Decisions in Node-negative and Node-positive Disease and Support Growing Adoption of Test.
	5. Traitements
What PCSK9 Is Telling Us About Drug Discovery [In the Pipeline] PCSK9 by itself is indeed meaningful – from a drug discovery standpoint, it’s probably the most actionable of the mutations discovered by modern sequencing.
Popular Prostate Cancer Therapy Is Short, Intense and Unproved [NY Times] The newer therapy is surging in popularity, but no one knows whether it is as effective in curing prostate cancer, or how its side effects compare.
	5.10 Traitements - Essais
Lilly gets positive abemaciclib phase 3 data, plots 2017 NDA [Fierce Biotech] Lilly did not disclose specific details on Monarch 2, but we believe that the data could make the upcoming ASCO meeting in June.
Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival [Lilly] Detailed efficacy and safety results will be presented at an upcoming medical meeting.
Laggard Lilly says its CDK 4/6 drug abemaciclib scored in PhIII, while rivals at Novartis, Pfizer sharpen their knives [EndPoints] Just a week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly is announcing that its long-awaited Phase III readout for its rival drug abemaciclib looks good. We won’t get the data until later.
Lilly's breast cancer drug combination succeeds key study [Reuters] Lilly's drug, abemaciclib, is part of the same new class of breast cancer treatments as Pfizer Inc's Ibrance, and Novartis AG's newly approved Kisqali.
	5.12 Immunothérapies
Tethered nanoparticles make tumor cells more vulnerable [MIT News] By tethering hundreds of tiny particles to the surfaces of tumor cells in the presence of a mechanical force, the researchers made the cells much more vulnerable to attack by a drug that triggers cancer cells to commit suicide.
	5.12.1 Immunothérapies - partenariats
Bristol-Myers Squibb, CytomX pen expanded $3.6B biobucks research deal [Fierce Biotech] CytomX gets $200 million upfront, as well as research funding, and can also look forward to $448 million in biobucks for each target, as well as tiered royalties, which could all be worth $3.6 billion in total (although this would require everything going exactly to plan).
First Trial Underway, CytomX Gets $200M More In Expanded Bristol Pact [Xconomy] CytomX’s Probody drugs are just one method of trying to build on the early success in cancer immunotherapy, which despite the hype and in some cases stunning results in some cancers still only helps a fraction of patients.
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases [BMS] By remaining inactive until they are activated by proteases in the tumor microenvironment, Probody therapeutics bind selectively to cells within tumor tissue with reduced binding to healthy tissue, potentially improving or creating a therapeutic window.
CTLA-4 bound for the clinic, Bristol-Myers hands CytomX $200M to kick off an expanded discovery pact [EndPoints] The biotech has its own PD-L1 checkpoint that just jumped into a Phase I/II study early this year. And its lead work with Bristol-Myers could provide a new and improved CTLA-4 that is supposed to avoid the kind of off-target toxicity that has limited Yervoy’s use.
	5.12.2 Immunothérapies - CAR-T
Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors [NCI] Dr. Sadelain and his colleagues used CRISPR to deliver a CAR gene to a precise location in the T-cell genome: the T-cell receptor alpha chain (TRAC) gene.
	5.2 Pharma
Losing Nemo: Array pulls skin cancer NDA for binimetinib [Fierce Biotech] The $1.75 billion market cap biotech was hit on the news premarket, with its shares down nearly 18%.
Array walks back its FDA pitch on binimetinib, derailing plans for commercial launch [EndPoints] Array BioPharma has some explaining to do. Fifteen months after the Boulder, CO-based biotech said that it had the data needed for its first approval of binimetinib for NRAS-positive melanoma, execs are walking back the application and its plans for a launch.
	5.4 Traitements - Economie
A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option [Health Affairs Blog] A more balanced approach to the current cry for accelerated access and lower prices could adapt and build on the 1992 HIV-only parallel track approach.
Health secretary backs 'easier' medicines access system [BBC News] Health-boards will decide whether or not to pay for a drug or treatment based on the "likely medical benefits" from September. Previously, patients had to demonstrate they were "exceptional" cases.
	5.9 AACR
Elizabeth M. Jaffee, MD, Named American Association for Cancer Research President-Elect 2017-2018 [AACR] Jaffee is an internationally recognized expert in cancer immunology, with specific expertise in preclinical and early clinical development of immunotherapies for breast and pancreatic cancers.
	6. Lutte contre les cancers
Care guidelines for cancer survivors often unclear [Reuters] Researchers examined cancer guidelines from North America and Europe that have been published since 2010 to advise doctors on the best ways to care for survivors of nine malignancies: breast, colorectal, lung, prostate, melanoma, uterine, bladder, thyroid and testicle. They found ambiguous recommendations in 83 percent of the guidelines.
	6.1 Observation
Radiotherapy risks are much higher for smokers [Cancer Research UK] The study shows that for non-smokers the long-term risk of death from lung cancer or heart attack – caused by radiation – is only 0.5 percent. But for smokers, this increases to around 5 percent.
	6.10.1 Politiques (USA)
Trump’s proposed 2018 budget launches a surprise attack on NIH [The Cancer Letter] The only explanation for slashing the NIH budget was offered on March 16, when Press Secretary Sean Spicer repeatedly referred to “duplicity” at NIH. Presumably, he meant “duplication.”
	6.6 Publications
What leads to bias in the scientific literature? New study tries to answer [Retraction Watch] Many have argued that scientists publish such data because that’s what is rewarded — by journals and, indirectly, by funders and employers, who judge a scientist based on his or her publication record. But a new meta-analysis in PNAS is saying it’s a bit more complicated than that.
	6.9 Controverses
Paul Glasziou and Iain Chalmers: Ill informed replications will increase our avoidable waste of research [BMJ Blogs] Replicability and research waste are intimately intertwined. Poor research design and poor reporting confound attempts at replication, and non-publication can hide “negative” studies that contradict “positive” published studies.